SOX2 and laryngotracheoesophageal cleft: In this sense, autoantibodies against p53, PGP9.5, SOX2, and MAGEA1 have been described to correlate with the overall survival of NSCLC patients (112), while a highly predicted autoantibody panel composed of 13 autoantibody biomarkers against SPATA19, TSPY3, GLS2, TCEA2, TSGA10, HMGN5, LUZP4, HDAC4, SPACA3, IMPDH1, TXN2, TFG, and PPP2R1A has been described to predict postoperative survival of LC patients (113).